Clinical Trial: A Real-world Study of Benmelstobart, Anlotinib and Chemotherapy Regimen as First-line Treatment for Extensive-stage Small-cell Lung Cancer

U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT06931145) titled 'A Real-world Study of Benmelstobart, Anlotinib and Chemotherapy Regimen as First-line Treatment for Extensive-stage Small-cell Lung Cancer' on April 09.

Brief Summary: The goal of this clinical trial is to evaluate the efficacy and safety of benmelstobart in combination with anlotinib and chemotherapy sequential benmelstobart in combination with anlotinib for the first-line treatment of extensive-stage small cell lung cancer.

Study Start Date: April 15

Study Type: INTERVENTIONAL

Condition: Extensive-stage Small Cell Lung Cancer

Intervention: DRUG: Benmelstobart

Benmelstobart injection, 1200 mg/dose, given once every 21 days,...